A carregar...
Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review
Brodalumab, a recombinant fully human monoclonal immunoglobulin IgG2 antibody with high affinity to human interleukin (IL)-17RA, is approved for the treatment of moderate-to-severe plaque psoriasis. In controlled clinical trials, brodalumab 210 mg administered by subcutaneous injection at weeks 0, 1...
Na minha lista:
| Publicado no: | Clin Cosmet Investig Dermatol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6628099/ https://ncbi.nlm.nih.gov/pubmed/31372022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CCID.S211938 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|